ALK and non-small cell lung carcinoma: For example, NCCN guidelines for NSCLC recommend testing for substitutions in EGFR, BRAF and KRAS; gene fusions in ALK, RET, ROS1, and NTRK1-3; and MET exon 14 skipping17.